Hasnain Faheem reported grant involving 321,672 shares of Aspen Neuroscience, Inc. at $0.00 for $0 on Nov 5, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Executive Chair
Executive Chair
Filed Nov 9, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
321,672Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
348,330Direct
Trade date
Nov 5, 2026Grant
Filed
Nov 9, 2026, 5:10 PM ET4-day reporting delay
Accession
0001193125-26-453834Code A · Transaction 396220
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

ASPE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ASPE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents the number of shares of common stock, which were 100% vested upon grant, to be delivered upon settlement of restricted stock unit award under the Reporting Person's executive chair offer letter on the designated deferred settlement date. The restricted stock units will be settled in one lump sum on the first trading day during calendar year 2027 as of which (A) the lock-up period applicable under the Reporting Person's lock-up agreement with the underwriters of the Issuer's initial public offering has expired or terminated and (B) the Reporting Person is permitted to sell shares of Common Stock in the open market under the Issuer's insider trading policy, but in all cases no later than December 31, 2027.